Hacker Newsnew | past | comments | ask | show | jobs | submit | barbarr's commentslogin

> He smirked. "Yes, I am."

The comments there are hilarious


> If you're going to post pet photos, at least learn how to expose properly. That shadow detail is completely crushed.

> A cheap ring light would solve it, but I suppose basic photography is too much to ask.

> Next time, try shooting in RAW and editing in Lightroom. Even a cat deserves decent composition.


I agree with these comments.


+1, the tokens from before a quantum hack will be transferred to a new fork. So at that moment, the value of BTC will go to 0 and the value of BTC v2 will take the value of BTC.

However at the moment, the community seems to be leaning towards pay-for-quantum-resistance [0]

[0] https://github.com/bitcoin/bips/pull/1670


I'm not so sure this will apply to BTC. It more or less has the staying power that it has because it hasn't changed at all, in fact pretty much everyone involved with it has resisted changing it, and it's not obvious there's anyone with enough political capital to make the fork, because anyone, right now, can make a fork of BTC and none of them have ever done well.


It will change if it has to. When everyone knows they have to do something it tends to actually happen. See COVID lockdowns, for example.


This and stock buybacks make me question company valuations


Stock buyback is effectively just a dividend with a different tax implication: reducing the number of shares in circulation raises the ownership stake of the remaining shares


> Stock buyback is effectively just a dividend with a different tax implication

Not just different, it specifically a lower tax rate assuming that the stockholder has held long enough to use the long term capital gains tax rate (which lower than the dividend tax rate).


[in the US]


Stock buyback isn't a total scam as it seems, but it does mean "we can't figure out any productive use case for this cash in advancing R&D or scaling our business anymore" which is still pretty worrying


By that logic, any profit a company distributes to shareholders is worrying.


I suppose stock buybacks are similar to dividends in that regard


It’s more like, “the executives with lots of shares can’t see how to make the company grow, so they’ll just use profits to pump up the share price for their gain”.

I deeply feel buybacks shouldn’t be illegal but treated shamefully.

Instead of using profits to build up long term savings or fund R&D, they basically choose to do as little as possible.

There is no vision.


Realistically, if the execs think they can't do R&D then they can't. If they tried they would just waste the money.


> Instead of using profits to build up long term savings or fund R&D, they basically choose to do as little as possible.

Isn't buying stock a form of long term savings? After all, they can always sell that stock when they want to "withdraw".

Sure, they may not get the same return as simply stashing it into a bank account, but it's also a statement of confidence in their future: "We are sure that our stock will outperform every other option there is for storing our money, because our long-term plans include extracting more profit from the market."


Should companies never pay dividends?


Investments into vision can juice the stock price too. So they would do it if they had good realistic inspiring ideas


Instagram reels are gonna get crazy


You see the one with the dolphin on the trampoline?


Those `nature is amazing type of videos` are already flooded with AI


Why is apple doing protein folding?


Apple has an ML research group. They do a mixture of obviously-Apple things, other applications, generally useful optimizations, and basic research.

https://machinelearning.apple.com/


This may not be the actual reason in this case, but I think it's good to be aware of: A non-zero chunk of "ai for science" research done at tech companies is basically done for marketing. Even in cases where it's not directly beneficial for the companies products or is unlikely to really lead to anything substantial, it is still good for "prestige"


No idea, but can I be signed up for R&D jobs where you don't necessarily build something generating revenue?

Maybe these are just projects they use to test and polish their AI chips? Not sure.


Local inference. I imagine they have an interest in making this and other cutting edge models small enough to be possible to do quick inference on their desktop machines. The article shows that, with Figure 1E demonstrating inference on an M2 Max 64 GB.

Frankly, it's a great idea. If you are a small pharma company, being able to do quick local inference removes lots of barriers and gatekeeping. You can even afford to do some Bayesian optimization or RL with lab feedback on some generated sequences.

In comparison, running AlphaFold requires significant resources. And IMHO, their usage of multiple alignments is a bit hacky, makes performance worse on proteins without close homologs, and requires tons of preprocessing.

A few years back, ESM from Meta already demonstrated that alignment-free approaches are possible and perform well. AlphaFold has no secret sauce, it's just a seq2seq problem, and many different approaches work well, including attention-free SSMs.


I think people often interpret a bit too much. Perhaps it’s just some researchers who got enough freedom to run and publish interesting work within apple. For a company like apple it makes sense to have a research lab with considerable freedoms even if protein folding is not a core interest, which is why you see it published but not the formula for the new Corning Gorilla glass…


Will be fascinating to see how the market breaks down in the future, will enough people want a third best model they can run on prem, or will people all be fighting in line for the top models that are a few cents more per token on supercomputers.


To sell computers? 20 years ago, Apple had scientific poster sessions at WWDC and worked to bring PyMol to the Mac. The pictures of proteins you see in the paper were generated with PyMol as are probably >50% of the protein images in scientific papers for the last 15 years.


If Warren Delano (the author of PyMol) were still with us, I think he would be amazed at where we are now with AlphaFold, and all the rest. At least what he hoped for, that software like this would be open source and peer-reviewable, has mostly held true.


Probably because ByteDance and Facebook (spun out into EvolutionaryScale) are doing it


They're jealous they haven't won a Nobel prize


Reputation laundering?


They have a much better reputation that most companies. I think they're doing okay compared to google, facebook, oracle, etc. Few people are going to think a corp is "doing good" but reputation does still matter somewhat.


If more people read the cases against Apple by the DOJ & the EU, they probably wouldn't have such a high opinion of Apple.


What’s there to launder? Perhaps they shouldn’t have as good a reputation as they do, but you can’t deny they do have a good reputation.


Reputation of what? They are just an office appliance company.


You're confusing your opinion of the company with the perception by the general public. Apple's definitely not perceived as 'an office appliance company' by your average person. It's considered a high-end luxury brand by many[1].

1: https://www.researchgate.net/publication/361238549_Consumer_...


I think you mean high-tech brand, which the linked article affirms.


I think their public sales data shows Apple sells mainly to consumers, and mainly iPhones at that.

Like 1980s SONY, they are the top of the line consumer electronics giant of the time. The iPhone is even more successful than the Walkman or Trinitron TVs.

They also sell the most popular laptops,to consumers as well as corporate. Like SONY’s VAIO but more popular again.


The move in consumer electronics leadership from Japan to the US, Korea, and now China is probably pretty interesting to understand.

Can anyone recommend a good book or article about this?


Ah, I see where we went wrong here, you never specified that you meant reputation in your mind only. FYI, “reputation” is usually considered to be related to a general public opinion, not your personal one.


Prowlly cuz Siri didn’t work out


How do you call the opposite of green washing? When you want to show that you are burning as much energy on training models as the others.


Was a bit scared by the headline at first


To what extent is YC's current strategy a form of "cookie-licking"? I.e. capture a small fraction of every plausible startup created by the next generation of students?


100% at this point. The industry's leading AI for start-up ideas has run out of AI for _____ suggestions. It was pretty obvious they were scraping the bottom of the barrel a month ago when I made this list from their current batch:

Acrely — AI for HVAC administration

Aden — AI for ERP operations

AgentHub — AI for agent simulation and evaluation

Agentin AI — AI for enterprise agents

AgentMail — AI for agent email infrastructure

AlphaWatch AI — AI for financial search

Alter — AI for secure agent workflow access control

Altur — AI for debt collection voice agents

Ambral — AI for account management

Anytrace — AI for support engineering

April — AI for voice executive assistants

AutoComputer — AI for robotic desktop automation

Autosana — AI for mobile QA

Autotab — AI for knowledge work

Avent — AI for industrial commerce

b-12 — AI for chemical intelligence

Bluebirds — AI for outbound targeting

burnt — AI for food supply chain operations

Cactus — AI for smartphone model deployment

Candytrail — AI for sales funnel automation

CareSwift — AI for ambulance operations

Certus AI — AI for restaurant phone lines

Clarm — AI for search and agent building

Clodo — AI for real estate CRMs

Closera — AI for commercial real estate employees

Clueso — AI for instructional content generation

cocreate — AI for video editing

Comena — AI for order automation in distribution

ContextFort — AI for construction drawing reviews

Convexia — AI for pharma drug discovery

Credal.ai — AI for enterprise workflow assistants

CTGT — AI for preventing hallucinations

Cyberdesk — AI for legacy desktop automation

datafruit — AI for DevOps engineering

Daymi — AI for personal clones

DeepAware AI — AI for data center efficiency

Defog.ai — AI for natural-language data queries

Design Arena — AI for design benchmarks

Doe — AI for autonomous private equity workforce

Double – Coding Copilot — AI for coding assistance

EffiGov — AI for local government call centers

Eloquent AI — AI for complex financial workflows

F4 — AI for compliance in engineering drawings

Finto — AI for enterprise accounting

Flai — AI for dealership customer acquisition

Floot — AI for app building

Fluidize — AI for scientific experiments

Flywheel AI — AI for excavator autonomy

Freya — AI for financial services voice agents

Frizzle — AI for teacher grading

Galini — AI guardrails as a service

Gaus — AI for retail investors

Ghostship — AI for UX bug detection

Golpo — AI for video generation from documents

Halluminate — AI for training computer use

HealthKey — AI for clinical trial matching

Hera — AI for motion design

Humoniq — AI for BPO in travel and transport

Hyprnote — AI for enterprise notetaking

Imprezia — AI for ad networks

Induction Labs — AI for computer use automation

iollo — AI for multimodal biological data

Iron Grid — AI for hardware insurance

IronLedger.ai — AI for property accounting

Janet AI — AI for project management (AI-native Jira)

Kernel — AI for web agent browsing infrastructure

Kestroll — AI for media asset management

Keystone — AI for software engineering

Knowlify — AI for explainer video creation

Kyber — AI for regulatory notice drafting

Lanesurf — AI for freight booking voice automation

Lantern — AI for Postgres application development

Lark — AI for billing operations

Latent — AI for medical language models

Lemma — AI for consumer brand insights

Linkana — AI for supplier onboarding reviews

Liva AI — AI for video and voice data labeling

Locata — AI for healthcare referral management

Lopus AI — AI for deal intelligence

Lotas — AI for data science IDEs

Louiza Labs — AI for synthetic biology data

Luminai — AI for business process automation

Magnetic — AI for tax preparation

MangoDesk — AI for evaluation data

Maven Bio — AI for BioPharma insights

Meteor — AI for web browsing (AI-native browser)

Mimos — AI for regulated firm visibility in search

Minimal AI — AI for e-commerce customer support

Mobile Operator — AI for mobile QA

Mohi — AI for workflow clarity

Monarcha — AI for GIS platforms

moonrepo — AI for developer workflow tooling

Motives — AI for consumer research

Nautilus — AI for car wash optimization

NOSO LABS — AI for field technician support

Nottelabs — AI for enterprise web agents

Novaflow — AI for biology lab analytics

Nozomio — AI for contextual coding agents

Oki — AI for company intelligence

Okibi — AI for agent building

Omnara — AI for agent command centers

OnDeck AI — AI for video analysis

Onyx — AI for generative platform development

Opennote — AI for note-based tutoring

Opslane — AI for ETL data pipelines

Orange Slice — AI for sales lead generation

Outlit — AI for quoting and proposals

Outrove — AI for Salesforce

Pally — AI for relationship management

Paloma — AI for billing CRMs

Parachute — AI for clinical evaluation and deployment

PARES AI — AI for commercial real estate brokers

People.ai — AI for enterprise growth insights

Perspectives Health — AI for clinic EMRs

Pharmie AI — AI for pharmacy technicians

Phases — AI for clinical trial automation

Pingo AI — AI for language learning companions

Pleom — AI for conversational interaction

Qualify.bot — AI for commercial lending phone agents

Reacher — AI for creator collaboration marketing

Ridecell — AI for fleet operations

Risely AI — AI for campus administration

Risotto — AI for IT helpdesk automation

Riverbank Security — AI for offensive security

Saphira AI — AI for certification automation

Sendbird — AI for omnichannel agents

Sentinel — AI for on-call engineering

Serafis — AI for institutional investor knowledge graphs

Sigmantic AI — AI for HDL design

Sira — AI for HR management of hourly teams

Socratix AI — AI for fraud and risk teams

Solva — AI for insurance

Spotlight Realty — AI for real estate brokerage

StackAI — AI for low-code agent platforms

stagewise — AI for frontend coding agents

Stellon Labs — AI for edge device models

Stockline — AI for food wholesaler ERP

Stormy AI — AI for influencer marketing

Synthetic Society — AI for simulating real users

SynthioLabs — AI for medical expertise in pharma

Tailor — AI for retail ERP automation

Tecto AI — AI for governance of AI employees

Tesora — AI for procurement analysis

Trace — AI for workflow automation

TraceRoot.AI — AI for automated bug fixing

truthsystems — AI for regulated governance layers

Uplift AI — AI for underserved voice languages

Veles — AI for dynamic sales pricing

Veritus Agent — AI for loan servicing and collections

Verne Robotics — AI for robotic arms

VoiceOS — AI for voice interviews

VoxOps AI — AI for regulated industry calls

Vulcan Technologies — AI for regulatory drafting

Waydev — AI for engineering leadership insights

Wayline — AI for property management voice automation

Wedge — AI for healthcare trust layers

Workflow86 — AI for workflow automation

ZeroEval — AI for agent evaluation and optimization


Please don't spam the threads with massive lists. It's enough to link to the information.

I'm not sure what this is supposed to show, other than that YC funds a lot of startups and a lot of them are working in AI, which is what you'd expect during any major tech wave.

In fact, YC funds so many startups that your list is actually misleadingly short, unless you meant to argue that AI startups are a low percentage.


You should create a startup based around an AI for collapsing lists if clicking [-] is too difficult and they are so annoying.

110 of those were from their summer 2025 batch of 170, so your statement is actually misleading unless you meant to argue that 65% is a low percentage.


Tecto AI is my favourite, as it forms the "AI for AI" ouroboros. Outrove also sounds confusing, because doesn't Salesforce already purport to have their own native AI features? And when I look them up, it seems they're just AI for recruiting, which is also what VoiceOS purports to do.

Looking up the founders is fascinating too. So many of them seem to have graduated and immediately started trailing what appear to be a string of back-to-back failed businesses, rarely with more than a year of staying power per attempt. It's hard to tell if that's "failing quickly" (desirable) or "frantically trying to get-rich-quick" (undesirable and what I run into in Melbourne most often).


This makes me want to reach for a tool that definitely has no AI whatsoever involved.

Specifically, the one described in https://news.ycombinator.com/item?id=45287474.


Incredible list. Thanks for sharing.


>Verne Robotics — AI for robotic arms

Kiko the Monkey

https://www.youtube.com/watch?v=1KaWPYOLuT8


This is art.


Please tell me your AI tool did that for you and you didn't do it manually


I'm actually the CEO of a startup that created the very first AI for AI for _____ list generation service. Already in our 347,985th round of funding, currently valued at $382,457,203.


Yo this is nuts lol!


I'm guessing they were looking for preferential delivery to certain cell types, and AAVs just happened to have best profile for those. If anything, LNPs might aggregate in the liver even more than AAVs, which can lead to even worse hepatotoxicity if an immune response happens.


I thought lipid nanoparticles were less prone to generate a immune reaction.


Lipid nanoparticle toxicity has long been an industry concern.

In a profile of Moderna back in 2016, Katalin Karikó (instrumental in the development of mRNA vaccines) mentioned this issue:

“I would say that mRNA is better suited for diseases where treatment for short duration is sufficiently curative, so the toxicities caused by delivery materials are less likely to occur” [1]

[1] https://www.statnews.com/2016/09/13/moderna-therapeutics-bio...


The issue was not the gene therapy itself, but the delivery mechanism. They used a virus to administer the gene therapy, and this virus (like most bloodstream impurities) aggregates in the liver. At low doses this is fine, but at high doses, your body's immune response will be laser-focused on the liver, and you die from the side effects of this response.


Lipid nanoparticles have exactly the same problem. They mostly concentrate in the liver.


Wouldn't anything concentrate in the liver?


if it's so obvious that this is going to produce these side effects, then why on earth did they gamble ?

(because, it definitely look like gambling, like "investors are behind us right now, so we have the money to do it, so let's do it before money runs out")


My brother in commenting they are doing trials. Trials are by nature bets. That’s how we move science forward.

They’re not trying to kill people. There is a hell of a lot more money in _not_ killing people.


Could hemodialysis prevent this?


Yes, dialysis is surprisingly good at filtering out viral particles, but... that's not desirable in this case. After all these viruses are carrying the therapeutic payload, if you filter them out then you might as well not introduce them in the first place.


Ok, I was thinking more of injecting viruses upstream, and filtering them out downstream (preventing them from entering the liver in the first place). Maybe you could even recycle them.


But maybe as treatment if liver problems are detected?


I suppose it's possible at that point, possibly to try and stem the process. The question is just how rapidly this condition emerges, and I suspect (although this is just a suspicion) that the time between onset and a severe reaction is fairly brief. Mostly though the problem is that this is a really complex, whole immune system reaction that's triggered by the AAV in the liver, but simply removing the intial cause probably wouldn't stop the cascade.

I took a look at some of the aftermath reports (i.e. https://pmc.ncbi.nlm.nih.gov/articles/PMC10638066/ and some others) which get into specific details about the course of treatment in several patients who died from this complication. The through-line is an aggressive use of several immune suppressing and modulating therapies to calm the cascade.

I have to admit I can't find any specific discussion about dialysis in that context, so I can only assume that removal of the viral particles would be a case of closing the barn door after the horse escaped.


Yeah I was suspecting they would do the treatment with immunosuppressants. Immune response is an unpredictable killer.


I imagine if these deaths could have been prevented by this one-line HN comment, they would have thought of it.

Maybe a better phrasing of your question would be:

> Why is hemodialysis ineffective for this?


The main reason for my question was this:

https://news.ycombinator.com/item?id=44609583


Hacker News Guidelines > "Be kind. Don't be snarky. Converse curiously; don't cross-examine. Edit out swipes."


My bad, snark wasn't my intent. I meant it literally. There was an accumulation of toxins, and it seems (to me at least) extremely unlikely that the researchers were not aware of dialysis as a way to remove toxins. So then let's jump to the next level of question.


Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact

Search: